Search results
Welcome to the winter edition of Look Forward. It’s packed full of news from our Conferences, the latest research news and an interview with Hassina Zeriri, one of our funded PhD students.
We have also included details of lots of ways you can get involved with Retina UK over the coming months, along with some suggested festive fundraising for the Christmas period.
Gyrate atrophy of the choroid and retina, shortened to gyrate atrophy, is an inherited disorder of protein metabolism characterised by progressive vision loss.
Introducing Splice Bio, a genetic medicines company with some exciting developments for Stargardt’s patients.
TPT and Sight Loss Councils: Cut it back campaign
A round-up of the latest research into inherited retinal conditions - February 2024.
Autosomal recessive inheritance means that the faulty gene is on an autosome (any chromosome other than the sex chromosomes) and that both copies need to be faulty to cause sight loss
Researchers have developed PEDF-based eye drops that show promise in slowing retinal degeneration in mice with retinitis pigmentosa, potentially offering a non-invasive treatment option for preserving vision in the future.
An American living with Leber congenital amaurosis 10 (LCA10) has become the first clinical trial participant in the world to receive a CRISPR gene editing treatment in vivo (inside the body).
James Birtley is a Retina UK supporter and volunteer who is living with retinitis pigmentosa. He is also a scientist with a particular interest in the structure of proteins, the complex molecules that form the building blocks of our bodies.
There are many ongoing clinical and laboratory studies around the world, exploring innovative approaches to treating inherited sight loss.
